XT
BCRX icon

XTX Topco’s BioCryst Pharmaceuticals BCRX Stock Holding History

XTX Topco’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
125,833
+101,071
+408% +$914K 0.02% 1576
2026
Q1 		$236K Buy
24,762
+7,651
+45% +$59.4K ﹤0.01% 2714
2025
Q4 		$133K Buy
+17,111
New +$124K ﹤0.01% 2550
2025
Q3 		– Sell
-95,201
Closed -$853K – 2569
2025
Q2 		$853K Buy
95,201
+7,812
+9% +$72.8K 0.04% 759
2025
Q1 		$655K Buy
87,389
+66,320
+315% +$535K 0.03% 827
2024
Q4 		$158K Sell
21,069
-10,601
-33% -$80.5K 0.01% 1644
2024
Q3 		$241K Sell
31,670
-125,276
-80% -$952K 0.02% 1331
2024
Q2 		$970K Buy
156,946
+117,607
+299% +$649K 0.08% 368
2024
Q1 		$200K Sell
39,339
-17,065
-30% -$96K 0.03% 1179
2023
Q4 		$338K Buy
56,404
+24,571
+77% +$142K 0.07% 532
2023
Q3 		$225K Sell
31,833
-69,112
-68% -$497K 0.04% 947
2023
Q2 		$711K Buy
100,945
+61,166
+154% +$491K 0.13% 199
2023
Q1 		$332K Buy
+39,779
New +$383K 0.07% 576
2022
Q3 		– Sell
-15,988
Closed -$169K – 1105
2022
Q2 		$169K Buy
+15,988
New +$165K 0.07% 509

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

XTX Topco's BCRX Position: Q2 2026 in Review

XTX Topco increased its BioCryst Pharmaceuticals (BCRX) stake by 408% in Q2 2026, buying an estimated $914K and bringing the position to 125,833 shares worth $1.26M. The position accounts for 0.02% of the portfolio, ranked #1576.

XTX Topco first reported a position in BCRX in Q2 2022 and has held it in 14 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • XTX Topco held 125,833 shares of BioCryst Pharmaceuticals worth $1.26M as of Q2 2026.
  • XTX Topco bought 101,071 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $914K.
  • BioCryst Pharmaceuticals made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1576 holding.
  • XTX Topco first reported a position in BioCryst Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.